CGEN — COMPUGEN LTD
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1119774 ·
Last close
$2.02
Market Cap
$191.34M
52W High
$3.24
52W Low
$1.43
ADV30
231,913
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 3,821,000 | 1,421,000 | -6,846,000 | -5,800,000 | 129,534,000 | 7,061,000 | 46,171,000 |
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 2,176,000 | 352,000 | -9,017,000 | -7,669,000 | 145,861,000 | 12,435,000 | 50,508,000 |
| Dec 2025 | 67,332,000 | 63,796,000 | 56,043,000 | 56,845,000 | 156,570,000 | 90,597,000 | 53,839,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-453,415,000
Inventory
—
Receivables
$2,338,000
ST Investments
$122,511,000
EBIT TTM
$30,704,000
Pretax Income TTM
$34,883,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$74,001,000
EBITDA
$30,676,000
Free Cash Flow
$22,217,000
Enterprise Value
$111,691,640
Total Cash
$125,300,000
Total Debt
$3,023,000
Shares Out
94,724,146
Trailing EPS
$0.38
Book Value
$0.94
ROE
50.6%
ROA
15.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 72,764,000 | 31,326,000 | 35,343,000 | 156,570,000 | 53,839,000 | 102,731,000 | 31,634,000 |
| Dec 2024 | 27,864,000 | -14,891,000 | -14,231,000 | 114,995,000 | 60,081,000 | 54,914,000 | 49,604,000 |
| Dec 2023 | 33,459,000 | -12,992,000 | -18,754,000 | 121,334,000 | 55,775,000 | 65,559,000 | -35,886,000 |
| Dec 2022 | 7,500,000 | -35,374,000 | -33,694,000 | 94,176,000 | 16,496,000 | 77,680,000 | -34,113,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.37
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARTV | Artiva Biotherapeutics, Inc. | $190.81M | $3.86 | — |
| IKT | Inhibikase Therapeutics, Inc. | $193.57M | $1.38 | — |
| DTIL | PRECISION BIOSCIENCES INC | $196.95M | $7.05 | — |
| PALI | PALISADE BIO, INC. | $181.07M | $1.01 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $206.36M | $0.82 | — |
News headlines (Yahoo Finance, 1h cache)
Compugen Ltd (CGEN) Q3 2026 Earnings Call Highlights: Revenue Doubles as Gilead and AstraZeneca ...
2026-11-12 23:03 · Yahoo
Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit
2026-11-10 12:00 · Yahoo
Compugen Ltd. Q3 2026 Earnings Call Summary
2026-11-09 17:44 · Yahoo
What Compugen (CGEN) Said on Its Q3 Earnings Call
2026-11-09 15:14 · Yahoo
Compugen: Q3 Earnings Snapshot
2026-11-09 12:06 · Yahoo
Compugen Reports Third Quarter 2026 Results
2026-11-09 12:00 · Yahoo
Compugen to Participate in November Investor Conferences
2026-11-03 12:00 · Yahoo
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
2026-10-05 21:02 · Yahoo
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 11:00 · Yahoo
Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ...
2026-08-06 01:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.